Vilobelimab  (Synonyms: CaCP-29, IFX-1)

Vilobelimab (CaCP-29, IFX-1) is a monoclonal anti-C5a antibody to the allergen C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. Vilobelimab acts as a C5a inhibitor, inhibiting neutrophil activation, chemotaxis, and reducing inflammatory signalling, and may be used in studies related to sepsis, COVID-19, etc^[1].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Chimeric

Vilobelimab selectively neutralises C5a in a dose-dependent manner without blocking the formation of the membrane attack complex and without leading to detectable safety concerns In certain clinical studies of patients suffering from severe sepsis and septic shock^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2250440-41-4

Liquid

Colorless to light yellow

[Vilobelimab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• [1]. Michael Bauer, et al. Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock-A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study). Crit Care Explor. 2021 Nov 17;3(11):e0577.  [Content Brief]